Let's see, this stock ran from $4 to $50 in one year on fundamentals that no longer exist. Company has no product, burning through cash at a high rate, new studies that could take a couple of years, new stock offerings coming to generate cash - further diluting price per share. I am surprised this is holding a $12. Don't forget the initial $4 starting point a year ago was after a 6:1 reverse stock split. Yes, we started out at about 60 cents. These analysts are nuts with that high of a short term price target. Bet we see $4 before $20.
Most of the new PTs are around $20. The efficacy of the drug is not in question, just longer approval hurdles than previously anticipated. With around $300M cash and very little debt, SRPT can operate for a very long time.